Atlas Venture, a Cambridge, MA-based venture capital firm investing in biotech innovation, closed its first Opportunity Fund, at $250m.
With Atlas Venture Opportunity Fund I (AVOF I), the firm will invest in existing portfolio companies as they progress through Series B financings and beyond, complementing early stage funds, which focus on new company formation.
Founded in 1993, the biotech venture capital firm works with scientists and entrepreneurs to translate high impact science into medicines for patients. Its seed-led venture creation strategy selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
The fund will be led by partners:
– Kevin Bitterman,
– Bruce Booth,
– Jean-François Formela,
– David Grayzel, and
– Jason Rhodes.